NUCRYST Pharmaceuticals announces year-e...(----------------------------------------...),Health

Revenue

Wound care product

revenue $ 6,235 $ 4,539 $ 20,092 $ 24,369

Milestone revenue 5,000 - 10,000 -

-------------------------------------------------------------------------

11,235 4,539 30,092 24,369

Costs

Manufacturing 3,502 2,750 14,477 16,053

Research and

development 1,454 1,862 6,303 11,162

General and

administrative 2,685 1,812 9,067 6,723

Depreciation and

amortization 94 86 355 430

Write down of

capital assets - 1,049 1,173 1,049

-------------------------------------------------------------------------

Income (loss) from

operations 3,500 (3,020) (1,283) (11,048)

Foreign exchange

(loss) gain (281) 1,109 (3,283) (298)

Interest income 109 242 685 1,123

Interest expense - - - (310)

-------------------------------------------------------------------------

Income (loss) before

income taxes and

cumulative effect of

a change in

accounting principle 3,328 (1,669) (3,881) (10,533)

Current income tax

(expense) recovery (140) 69 (140) 41

-------------------------------------------------------------------------

Income (loss) before

cumulative effect of

a change in

accounting principle 3,188 (1,600) (4,021) (10,492)

Cumulative effect of

a ch
'/>"/>